Glioma | Niche & Rare Disease Landscape & Forecast | US/EU5 | 2016
From disease basics to insightful analysis of market dynamics, Glioma | Disease Landscape & Forecast | United States, EU5 provides comprehensive disease coverage addressing critical aspects of the glioma pharmaceutical market based on detailed primary and secondary market research. Content pillars include a summary of disease etiology, pathophysiology, and drug targets; annualized epidemiological projections, including estimates of diagnosis and/or drug treatment; a deep examination of current therapies and medical practice; a review of top unmet needs; a thorough pipeline assessment, including launch timing, positioning, and peak sales of key late-phase drugs; a top-line review of pertinent market access themes; and an epidemiology-based, bottom-up market forecast with supporting tables, figures, and methods.
Questions Answered:
- How large is the treatable glioma population, and how will diagnosis/drug-treatment rates change over time?
- What is the current state of treatment in glioma? Which are the most important drugs and why? What are interviewed experts’ insights on current treatment options? What clinical needs remain unfulfilled?
- What pipeline products are most promising, and what sales/uptake could they secure in glioma? What therapies of note are progressing in earlier phases?
- What are the drivers and constraints in the glioma market, and how will the market evolve over the forecast period?
Scope:
Markets covered: United States, France, Germany, Italy, Spain, and the United Kingdom.
Primary research: 8 country-specific interviews with thought leaders.
Epidemiology: Diagnosed incident cases of low-grade glioma (WHO grade I-II), high-grade glioma (anaplastic glioma; WHO grade III), glioblastoma (WHO grade IV; primary cases ), and transformed cases of nonglioblastoma astrocytic glioma (WHO grade I-III; secondary cases).
Population segments in market forecast: First-line glioblastoma (newly diagnosed and transformed nonglioblastoma astrocytic glioma cases), second-line glioblastoma (first recurrence), and third-line glioblastoma (second recurrence).
Phase III: 6 drugs; Phase II: 15 drugs; coverage of selected preclinical and Phase I products.
